Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma

By: TheNewswire.com

March 09, 2023 at 07:53 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

Carriage Services Q1 Earnings Call Highlights ↗

Today 19:03 EDT

Via MarketBeat

Claritev Q1 Earnings Call Highlights ↗

Today 19:03 EDT

Via MarketBeat

CareTrust REIT Q1 Earnings Call Highlights ↗

Today 19:03 EDT

Via MarketBeat

Charles River Laboratories International Q1 Earnings Call Highlights ↗

Today 19:03 EDT

Via MarketBeat

Comstock Resources Q1 Earnings Call Highlights ↗

Today 19:03 EDT

Via MarketBeat

Recent Quotes

Symbol	Price	Change (%)
AMZN	272.68	+1.51 (0.56%)
AAPL	293.32	+5.88 (2.05%)
AMD	455.19	+46.73 (11.44%)
BAC	51.31	-1.44 (-2.73%)
GOOG	397.05	+1.75 (0.44%)
META	609.63	-7.18 (-1.16%)
MSFT	415.12	-5.65 (-1.34%)
NVDA	215.20	+3.70 (1.75%)
ORCL	195.95	+1.36 (0.70%)
TSLA	428.35	+16.56 (4.02%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.